TABLE 2

Biodistribution Data for 18F-FDG in C57BL/6 Mice Bearing Subcutaneously Xenotransplanted B16/F10 Murine Melanoma at 2 and 4 Hours After Injection and Fox Chase Scid Mice Bearing A375M Human Melanoma at 1 Hour After Injection

B16/F10A375M
18F-FDG2 h4 h1 h
Tumor10.86 ± 3.856.18 ± 1.041.61 ± 0.29
Blood0.37 ± 0.080.21 ± 0.080.53 ± 0.30
Muscle4.52 ± 2.272.27 ± 0.373.89 ± 1.14
Skin0.91 ± 0.390.82 ± 0.201.23 ± 0.38
Bone1.66 ± 0.481.32 ± 0.391.16 ± 0.17
Heart34.39 ± 10.9413.33 ± 3.565.66 ± 5.87
Liver1.57 ± 0.740.54 ± 0.120.97 ± 0.33
Lung3.91 ± 1.312.09 ± 0.362.90 ± 1.43
Kidney1.90 ± 0.310.71 ± 0.131.44 ± 0.43
Spleen2.83 ± 1.111.83 ± 0.342.38 ± 0.86
Brain4.09 ± 1.451.75 ± 0.224.29 ± 0.80
Intestine2.09 ± 0.771.49 ± 1.051.67 ± 0.53
Stomach2.30 ± 1.010.75 ± 0.421.45 ± 0.44
Pancreas2.99 ± 0.671.57 ± 0.631.68 ± 0.43
Tumor/blood ratio29.20 ± 4.9933.09 ± 13.513.49 ± 1.34
Tumor/muscle ratio2.57 ± 0.642.85 ± 1.010.44 ± 0.15
  • Data are expressed as normalized accumulation of activity in %ID/g ± SD (n = 3 for each group).